|
| 我国已上市治疗用重组蛋白类产品分析 |
| Analysis of recombinant protein or peptide products for therapeutic use in China |
| 投稿时间：2019-08-01 修订日期：2019-08-09 |
| DOI： |
| 中文关键词: 生物制品 重组蛋白多肽 已上市药品 技术分析 |
| 英文关键词: biological products recombinant protein or peptides marketed products technical analysis |
| 基金项目: |
|
| 摘要点击次数: 397 |
| 全文下载次数: 0 |
| 中文摘要: |
| 重组蛋白类生物药物是采用DNA重组技术或其他生物技术生产的蛋白类治疗药物。这类药物一般是人类天然存在的或与天然蛋白结构类似的蛋白质或多肽,量微而活性强,相对来说副作用小、安全性高。本文对我国已上市的重组蛋白多肽类药物的基本情况、技术代次、治疗领域等进行了回顾梳理,找出我国治疗用重组蛋白多肽类产品存在的不足,明确未来努力方向。 |
| 英文摘要: |
| Recombinant protein biopharmaceuticals are protein-based therapeutic drugs produced by recombinant DNA technology or other biotechnology. Such drugs are generally proteins or polypeptides which are naturally occurring in humans or similar in structure to natural proteins, relatively speaking, with the advantages of small side effects and high safety. In this paper, we reviewed and analyzed the basic situation, technical generation and therapeutic field of recombinant protein peptide drugs that have been listed in China. At the same time, finded out the shortcomings of therapeutic protein peptide products in China and clarified the direction of efforts. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |